Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;19(2):74-85.
doi: 10.1200/OP.22.00342. Epub 2022 Oct 12.

The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia

Jennifer H Cooperrider  1 , Navika Shukla  2 , Mariam T Nawas  1 , Anand Ashwin Patel  1
Affiliations
Review

The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia

Jennifer H Cooperrider et al. JCO Oncol Pract. 2023 Feb.

Abstract

Since 2017, the number of agents for acute myeloid leukemia (AML) has rapidly expanded. Given the increased therapeutic options, better identification of high-risk subsets of AML and more refined approaches to patient fitness assessment, the decisions surrounding selection of intensive chemotherapy versus lower-intensity treatment have grown increasingly more nuanced. In this review, we present available data for both standard and investigational approaches in the initial treatment of AML using an intensive chemotherapy backbone or a lower-intensity approach. We summarize management strategies in newly diagnosed secondary AML, considerations around allogeneic stem-cell transplantation, and the role of maintenance therapy. Finally, we highlight important areas of future investigation and novel agents that may hold promise in combination with standard therapies.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jennifer H. Cooperrider

Employment: AbbVie

Anand Ashwin Patel

Research Funding: Bristol Myers Squibb/Celgene (Inst), Servier (Inst), Pfizer (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Our treatment approach to newly diagnosed AML and areas of investigation. HMA, hypomethylating agent; IC, intensive chemotherapy; ITD, internal tandem duplication; KIT, receptor tyrosine kinase; MRC, myelodysplasia-related changes; sAML, secondary acute myeloid leukemia; t-AML, therapy-related AML; TKD, tyrosine kinase domain; VEN, venetoclax.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. : Cancer statistics, 2021. CA Cancer J Clin 71:7-33, 2021 - PubMed
    1. SEER : Cancer State Facts: Leukemia‐Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html
    1. Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179-4187, 2009 - PubMed
    1. Kantarjian H, Ravandi F, O’Brien S, et al. : Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422-4429, 2010 - PMC - PubMed
    1. Daver N, Wei AH, Pollyea DA, et al. : New directions for emerging therapies in acute myeloid leukemia: The next chapter. Blood Cancer J 10:107, 2020 - PMC - PubMed

Publication types

MeSH terms